PMOS is lifelong, but its features are not fixed: they change with weight, insulin resistance and age. Insulin resistance has markers that can be measured and re-measured, so whether it is changing can be checked rather than assumed.

PCOS Is Now PMOS: The Metabolic Story Behind Infertility

For years, one of the most common conditions in women’s health was named after a feature many people with it do not have. In May 2026 the name changed, and the new one says what my fertility work has been built on for close to two decades: this is an endocrine and metabolic condition, not only an ovarian one.

If you have been told you “don’t have PCOS” because your ovaries looked normal on a scan — yet you live with irregular cycles, stubborn weight, low mood, difficult skin, or unexplained trouble conceiving — this article is written for you. Where PMOS is behind them, its root is endocrine and metabolic as much as ovarian, and that changes what is worth measuring.

From PCOS to PMOS — the name catches up with the biology

In May 2026, an international consensus of clinicians, researchers and patient organisations, published in The Lancet, renamed polycystic ovary syndrome (PCOS) polyendocrine metabolic ovarian syndrome (PMOS).¹ The change was not cosmetic. The old name was judged inaccurate because it implied cysts — which are in fact follicles whose development has stalled — and because it hid the condition’s endocrine and metabolic features. It affects about one in eight women.¹

The consensus found that the old name contributed to delayed diagnosis, fragmented care and stigma.¹ The new name reflects what the metabolic evidence has shown for years: insulin acts on the ovary directly,² and insulin resistance is common in the condition at every body weight [Established — human, mechanistic and clamp studies].³ The roles of inflammation and of cellular energy are less settled, and each is graded where it appears below.

Not everyone agrees. Some reproductive medicine specialists argue that “PMOS” risks underplaying the biological centrality of ovarian dysfunction, and that consensus methodology alone does not establish biological validity.⁴ The debate is worth naming rather than hiding — and the clinical case for investigating the metabolic terrain does not depend on which name wins [contested].

On terminology in this article

This practice uses PMOS — polyendocrine metabolic ovarian syndrome — as the accurate successor to PCOS, the term you are most likely to have been given and to search for. They refer to the same condition; PMOS is used throughout below.

A whole-body condition that wore a gynaecological label

Because the condition is endocrine and metabolic as well as ovarian, its signs are not confined to the ovaries. Across a lifetime they can surface as a shifting set of presentations:

Adolescence: persistent acne, irregular or absent periods.
Twenties and thirties: weight that resists effort, low mood and anxiety, blood-sugar swings (the irritable “hangry” low, the heavy post-meal slump), and difficulty conceiving — including unexplained infertility, anovulation, and progesterone deficiency.
Fertility treatment: a strong, sometimes excessive response to ovarian stimulation, with a higher risk of ovarian hyperstimulation syndrome [Established — clinical guideline].⁵
Pregnancy: a higher rate of miscarriage; higher rates of gestational diabetes and gestational hypertension, which hold when weight is matched; and of pre-eclampsia and preterm birth, which in weight-matched studies follow weight [Established — human, meta-analysis].⁶⁷
Midlife and beyond: a higher risk of type 2 diabetes and of cardiovascular disease [Established — clinical guideline; human observational, umbrella review].⁵⁸

The thread that runs through every stage is metabolic.

Why the old lens missed so many people

Two assumptions in the old model sent people away undiagnosed.

The first was treating the scan as the test. Under the international criteria, a scan is not needed when irregular cycles and raised androgens are both present, yet people with both have been told they did not have the condition because their ovaries looked normal [Established — clinical guideline].⁵

The second, less discussed, was weight. The stereotype is an overweight patient — so a slim one may not be investigated for it. Yet insulin resistance is common in PMOS at every body weight: in clamp studies, the reference method, insulin sensitivity was on average 27% lower than in women without the condition, independently of BMI, and excess weight adds to it [Established — human, meta-analysis].³ Not every lean woman with PMOS is insulin resistant,² which is a reason to measure it rather than assume it. The same is true of type 2 diabetes and cardiovascular disease, and more so in East and South Asian populations, whose risk rises at a lower BMI than the standard cut-off of 25 [Established — WHO expert consultation].⁹ The “thin outside, fat inside” (TOFI) pattern — normal weight, with fat stored around the organs and insulin already raised — describes the patient who is told that being slim means being metabolically well. I see it often in my Korean and other East Asian patients [Clinical Heuristic].

The consequence of both assumptions is the same: the condition is dismantled into fragments and parcelled out across specialties. Acne to dermatology, low mood to psychology, irregular cycles to one clinic, subfertility to another, raised blood sugar to diabetes care: the fragmented care the consensus describes.¹ In an Australian community study, about two in three women who met the diagnostic criteria had never been diagnosed [Established — human observational].¹⁰

The PMOS reframing matters precisely because it legitimises investigating that current directly — across body sizes, and as one connected system — rather than waiting for an ovary to look a particular way.

The metabolic engine room

Insulin resistance: the central current

Insulin resistance is a core feature, present across body sizes, and it links the reproductive picture to the metabolic one. Raised insulin acts with LH on the ovary to increase androgen production — behind acne, irregular cycles and anovulation — and lowers the liver’s output of SHBG, so more testosterone circulates free [Established — human and in vitro].²

But this is not a one-hormone system; the whole endocrine network moves together. When ovulation fails, the corpus luteum that should produce progesterone never forms — so progesterone deficiency follows directly from anovulation [Established]. Autoimmune thyroiditis is found more often than in women without the condition (odds ratio 2.38 across 18 studies) [Established — human observational, meta-analysis],¹¹ compounding cycle disruption, mood and metabolic rate. And the stress axis belongs in the picture: cortisol and HPA-axis activity interact with insulin and androgens rather than acting alone [Emerging]. Which node drives which differs from person to person, so each result is read beside the others rather than on its own.

Cellular energy and egg quality

An egg depends on its mitochondria more than almost any other cell: the oocyte is the richest cell in the body in mitochondria, and relies on them to become competent for fertilisation and early development [Established — review].¹² In human ovarian tissue, oocytes from older women show more oxidative damage and lower mitochondrial function [Emerging — human tissue].¹³ Whether the insulin resistance of PMOS acts on the egg through the same route has not been shown [Theoretical]. The energy argument is set out in the metabolic-bioenergetic approach to fertility.

Inflammation and cumulative load

Chronic low-grade inflammation is a shared feature of PMOS, obesity and type 2 diabetes, and endocrine-disrupting chemicals are under study as contributors [Emerging — human observational; reviews].¹⁴¹⁵ Inflammation has markers that can be measured and re-measured; for most chemical exposures there is no routine clinical test.

Fertility is often a couple’s picture

A pattern I see often: when a woman presents with this metabolic-reproductive profile, her partner frequently carries a male version of the same terrain [Clinical Heuristic]. Couples share a kitchen, meal times, sleep hours, activity and stress, and their metabolic health tends to travel together: in a review covering more than 75,000 couples, having a spouse with diabetes was linked to a 26% higher risk of diabetes oneself, a link that weakened once weight was taken into account [Established — human observational, meta-analysis].¹⁶

The practical consequence is simple and often overlooked: male factor should never be assumed absent, and a metabolic approach that looks at only one partner sees half the picture.

What this means for IVF — and for trying naturally

In women with overweight or obesity, preconception lifestyle programmes raise the rate of natural conception compared with no programme [Established — human RCT, meta-analysis];¹⁷¹⁸ whether they raise live births differs between reviews [contested].¹⁷¹⁸ Most of these trials were not limited to PMOS. In randomised trials in pregnancy, a Mediterranean diet lowered the risk of gestational diabetes and preterm birth [Established — human RCT, meta-analysis; mostly White European women].¹⁹

For fertility treatment, the picture is more nuanced. Natural conceptions rise, as above, but the two largest randomised trials of a programme before treatment did not show more healthy births. In LIFEstyle, 577 women with a BMI of 29 or more either followed a six-month programme and then had 18 months of treatment, or had 24 months of treatment from the start: a healthy baby born vaginally at term within two years followed in 27.1% against 35.2% [Established — human RCT, null].²⁰ In FIT-PLESE, 379 women with obesity and unexplained infertility lost 6.6% of their weight over 16 weeks with meal replacements and a weight-loss drug, and the metabolic syndrome fell from 53% to 32%; after three cycles of treatment, healthy live births were 12.2%, against 15.2% in women who exercised without losing weight, a difference that was not significant [Established — human RCT, null].²¹ Its authors concluded that better metabolic health may not translate into more births; the trial tested one rapid programme, so it cannot say whether a slower one would. What mechanism makes plausible — and what I assess for in the clinic — is that a better-prepared metabolic terrain (improved insulin sensitivity, lower inflammation) supports how a body tolerates and responds to a cycle [Clinical Heuristic].

What this article does not claim

Nothing here promises conception or a particular IVF result. Outcomes are multifactorial and cannot be guaranteed. The case for a metabolic-first approach rests on mechanism and on what is measurable — not on outcome claims.

The downstream stakes: pregnancy, and the decades after

Taking the metabolic root seriously is not only about conceiving. PMOS is associated with a modestly higher risk of cardiovascular disease later in life: under 1.5-fold in an umbrella review of 32 reviews [Established — human observational, umbrella review].⁸ That is a reason to measure cardiometabolic markers early, whatever the fertility plan. With few or no ovulations, the lining is exposed to oestrogen without the progesterone that ovulation brings, and over time it can thicken abnormally (endometrial hyperplasia) [Established — clinical guideline].⁵ Raised weight and raised glucose before pregnancy are known risks for gestational diabetes and pre-eclampsia [Established]; whether improving them before conception lowers those risks has not been shown consistently in trials [contested].¹⁷

What a metabolic-first approach looks like here

It follows directly from everything above: I do not build treatment on a diagnosis label.

Because two people with the same diagnosis can have entirely different drivers, the first task is to map your circuits. That means looking upstream: insulin and blood-sugar regulation, thyroid function and the cortisol rhythm, inflammation and digestion, nutrient status and energy metabolism, and the partner’s metabolic picture where relevant — the work of functional lab testing. From there, an individualised plan draws on nutrition and targeted dietary change, acupuncture, herbal medicine where indicated, and lifestyle and load-reduction strategies — chosen for the terrain we actually find, not the label on the referral. This is the shape of natural fertility support and hormone optimisation as I practise them.

Key takeaways

In May 2026 an international consensus published in The Lancet renamed polycystic ovary syndrome (PCOS) polyendocrine metabolic ovarian syndrome (PMOS), because the old name implied cysts and hid the condition’s endocrine and metabolic features [Established — consensus statement].
In clamp studies, women with PMOS had on average 27% lower insulin sensitivity than women without it, independently of body mass index [Established — human, meta-analysis].
In an Australian community study, about two in three women who met the criteria for the condition had never been diagnosed [Established — human observational].
In the LIFEstyle and FIT-PLESE randomised trials, a lifestyle programme before fertility treatment in women with obesity did not show an increase in healthy births [Established — human RCT, null].
Without ovulation no corpus luteum forms, so the endometrium is exposed to oestrogen without progesterone, which raises the risk of endometrial hyperplasia [Established].

Frequently asked questions

I was told I don’t have PCOS because my ovaries looked normal — could I still have it?

It is possible. Under the international criteria, the condition is diagnosed from two of three features: irregular or absent ovulation; raised androgens, on a blood test or as acne or excess hair; and, in adults, polycystic ovaries on a scan or a raised AMH. A scan is not needed when the first two are present, so normal-looking ovaries do not rule it out.⁵ Other causes of irregular cycles, such as thyroid disease and a raised prolactin, are ruled out first.

What is the difference between PCOS and PMOS?

They are the same condition. PMOS — polyendocrine metabolic ovarian syndrome — is the name adopted in 2026 to describe it more accurately as a multi-system endocrine and metabolic disorder rather than a primarily ovarian one.

Can men have a version of this?

The condition is only diagnosed in women. In a study of health records, a higher genetic risk score for it was linked to high blood pressure more strongly in men than in women [Emerging — human genetic association].²² Partners also share much of their metabolic risk through how they live: across more than 75,000 couples, having a spouse with diabetes was linked to a 26% higher risk of diabetes oneself [Established — human observational, meta-analysis].¹⁶ Both partners’ metabolic health is relevant to fertility.

Can improving my metabolism really affect IVF?

In women with overweight or obesity, lifestyle programmes raise the rate of natural conception. Before fertility treatment, the two largest randomised trials did not show more healthy births, even where the programme improved metabolic health.²⁰²¹

Is it reversible?

PMOS is lifelong, but its features are not fixed: they change with weight, insulin resistance and age.⁵ Insulin resistance has markers that can be measured and re-measured, so whether it is changing can be checked rather than assumed.

References

Teede HJ, Bahri Khomami M, Morman R, Laven JSE, Joham AE, Costello MF, et al. Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: a multistep global consensus process. Lancet. 2026;407(10545):2329–2339. doi:10.1016/S0140-6736(26)00717-8. PMID: 42119588. [Established — consensus statement] ↩︎↩︎↩︎↩︎
Diamanti-Kandarakis E, Dunaif A. Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. Endocr Rev. 2012;33(6):981–1030. doi:10.1210/er.2011-1034. PMID: 23065822. [Established — review] ↩︎↩︎↩︎
Cassar S, Misso ML, Hopkins WG, Shaw CS, Teede HJ, Stepto NK. Insulin resistance in polycystic ovary syndrome: a systematic review and meta-analysis of euglycaemic-hyperinsulinaemic clamp studies. Hum Reprod. 2016;31(11):2619–2631. doi:10.1093/humrep/dew243. PMID: 27907900. [Established — human, meta-analysis] ↩︎↩︎
Longo M, La Marca A. PCOS is here to stay: does ‘PMOS’ truly reflect biological reality? Reprod Biomed Online. 2026;53(5):105883. doi:10.1016/j.rbmo.2026.105883. PMID: 42600548. [contested — commentary] ↩︎
Teede HJ, Tay CT, Laven J, Dokras A, Moran LJ, Piltonen TT, et al. Recommendations from the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. Hum Reprod. 2023;38(9):1655–1679. doi:10.1093/humrep/dead156. PMID: 37580037. [Established — clinical guideline] ↩︎↩︎↩︎↩︎↩︎↩︎
Bahri Khomami M, Joham AE, Boyle JA, Piltonen T, Silagy M, Arora C, et al. Increased maternal pregnancy complications in polycystic ovary syndrome appear to be independent of obesity — a systematic review, meta-analysis, and meta-regression. Obes Rev. 2019;20(5):659–674. doi:10.1111/obr.12829. PMID: 30674081. [Established — human, meta-analysis] ↩︎
Bahri Khomami M, Joham AE, Boyle JA, Piltonen T, Arora C, Silagy M, et al. The role of maternal obesity in infant outcomes in polycystic ovary syndrome — a systematic review, meta-analysis, and meta-regression. Obes Rev. 2019;20(6):842–858. doi:10.1111/obr.12832. PMID: 30785659. [Established — human, meta-analysis] ↩︎
Okoth K, Chandan JS, Marshall T, Thangaratinam S, Thomas GN, Nirantharakumar K, et al. Association between the reproductive health of young women and cardiovascular disease in later life: umbrella review. BMJ. 2020;371:m3502. doi:10.1136/bmj.m3502. PMID: 33028606. [Established — human observational, umbrella review] ↩︎↩︎
WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet. 2004;363(9403):157–163. doi:10.1016/S0140-6736(03)15268-3. PMID: 14726171. [Established — expert consultation] ↩︎
March WA, Moore VM, Willson KJ, Phillips DI, Norman RJ, Davies MJ. The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Hum Reprod. 2010;25(2):544–551. doi:10.1093/humrep/dep399. PMID: 19910321. [Established — human observational] ↩︎
Bahreiny SS, Ahangarpour A, Amraei M, Mansouri Z, Pirsadeghi A, Kazemzadeh R, et al. Autoimmune thyroid disorders and polycystic ovary syndrome: tracing links through systematic review and meta-analysis. J Reprod Immunol. 2024;163:104215. doi:10.1016/j.jri.2024.104215. PMID: 38402811. [Established — human observational, meta-analysis] ↩︎
May-Panloup P, Boucret L, Chao de la Barca JM, Desquiret-Dumas V, Ferré-L’Hotellier V, Morinière C, et al. Ovarian ageing: the role of mitochondria in oocytes and follicles. Hum Reprod Update. 2016;22(6):725–743. doi:10.1093/humupd/dmw028. PMID: 27562289. [Established — review] ↩︎
Smits MAJ, Schomakers BV, van Weeghel M, Wever EJM, Wüst RCI, Dijk F, et al. Human ovarian aging is characterized by oxidative damage and mitochondrial dysfunction. Hum Reprod. 2023;38(11):2208–2220. doi:10.1093/humrep/dead177. PMID: 37671592. [Emerging — human tissue] ↩︎
Di Lorenzo M, Cacciapuoti N, Lonardo MS, Nasti G, Gautiero C, Belfiore A, et al. Pathophysiology and nutritional approaches in polycystic ovary syndrome (PCOS): a comprehensive review. Curr Nutr Rep. 2023;12(3):527–544. doi:10.1007/s13668-023-00479-8. PMID: 37213054. [Emerging — review] ↩︎
Sadeghi HM, Adeli I, Calina D, Docea AO, Mousavi T, Daniali M, et al. Polycystic ovary syndrome: a comprehensive review of pathogenesis, management, and drug repurposing. Int J Mol Sci. 2022;23(2):583. doi:10.3390/ijms23020583. PMID: 35054768. [Emerging — review] ↩︎
Leong A, Rahme E, Dasgupta K. Spousal diabetes as a diabetes risk factor: a systematic review and meta-analysis. BMC Med. 2014;12:12. doi:10.1186/1741-7015-12-12. PMID: 24460622. [Established — human observational, meta-analysis] ↩︎↩︎
Lan L, Harrison CL, Misso M, Hill B, Teede HJ, Mol BW, et al. Systematic review and meta-analysis of the impact of preconception lifestyle interventions on fertility, obstetric, fetal, anthropometric and metabolic outcomes in men and women. Hum Reprod. 2017;32(9):1925–1940. doi:10.1093/humrep/dex241. PMID: 28854715. [Established — human RCT, meta-analysis] ↩︎↩︎↩︎
Hoek A, Wang Z, van Oers AM, Groen H, Cantineau AEP. Effects of preconception weight loss after lifestyle intervention on fertility outcomes and pregnancy complications. Fertil Steril. 2022;118(3):456–462. doi:10.1016/j.fertnstert.2022.07.020. PMID: 36116799. [Established — review of randomised trials] ↩︎↩︎
Yang J, Song Y, Gaskins AJ, Li LJ, Huang Z, Eriksson JG, et al. Mediterranean diet and female reproductive health over lifespan: a systematic review and meta-analysis. Am J Obstet Gynecol. 2023;229(6):617–631. doi:10.1016/j.ajog.2023.05.030. PMID: 37506751. [Established — human RCT and cohort, meta-analysis] ↩︎
Mutsaerts MA, van Oers AM, Groen H, Burggraaff JM, Kuchenbecker WK, Perquin DA, et al. Randomized trial of a lifestyle program in obese infertile women. N Engl J Med. 2016;374(20):1942–1953. doi:10.1056/NEJMoa1505297. PMID: 27192672. [Established — human RCT, null] ↩︎↩︎
Legro RS, Hansen KR, Diamond MP, Steiner AZ, Coutifaris C, Cedars MI, et al. Effects of preconception lifestyle intervention in infertile women with obesity: the FIT-PLESE randomized controlled trial. PLoS Med. 2022;19(1):e1003883. doi:10.1371/journal.pmed.1003883. PMID: 35041662. [Established — human RCT, null] ↩︎↩︎
Actkins KV, Jean-Pierre G, Aldrich MC, Velez Edwards DR, Davis LK. Sex modifies the effect of genetic risk scores for polycystic ovary syndrome on metabolic phenotypes. PLoS Genet. 2023;19(5):e1010764. doi:10.1371/journal.pgen.1010764. PMID: 37256887. [Emerging — human genetic association] ↩︎